Moleac is at World Stroke Congress (WSC) in Singapore!
Moleac is at the World Stroke Congress (WSC) in Singapore! Visit us at Booth 25 and talk with our...
ISRRA meeting in Vienna
Moleac was honoured to support the International Stroke Recovery and Rehabilitation Alliance...
Moleac’s 20th Anniversary
Moleac celebrates its 20th Anniversary! We are proud of what we have achieved over the past 20...
World Stroke Day 2022
World Stroke Day is approaching! At Moleac, we are committed to increase stroke awareness and to...
Moleac is a certified Eco Office by the Singapore Environment Council
Moleac is excited to annouce that out Singapore office has been certified ECO-Office provided by...
NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries
Singapore, June 6, 2022, Moleac is pleased to announce the release of the results of the SATURN...
NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results,...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval...
